Drug interactions with omeprazole
Pro Research Analysisby 
Searched over 200M research papers
Omeprazole Drug Interactions: Key Mechanisms and Clinical Risks
Omeprazole, a widely used proton pump inhibitor (PPI), is known for its potential to interact with many other drugs, primarily through effects on drug metabolism and absorption. Understanding these interactions is crucial for safe and effective therapy, especially in patients taking multiple medications 110.
Cytochrome P450 Enzyme Interactions
Omeprazole is metabolized mainly by the cytochrome P450 system, particularly CYP2C19 and CYP3A4. It can inhibit these enzymes, leading to increased blood levels of drugs that are metabolized by the same pathways, such as diazepam, phenytoin, warfarin, and clozapine 124. The inhibition is not uniform across all drugs, and omeprazole shows a differential affinity for specific P450 isozymes, meaning some drugs are more affected than others .
Omeprazole and its metabolites can reversibly and time-dependently inhibit CYP2C19 and CYP3A4, contributing significantly to drug-drug interactions (DDIs). Metabolites may account for 30–63% of the in vivo hepatic interactions, so their role should not be overlooked in risk assessments .
Impact of Genetic Variability
The extent of omeprazole’s interactions can depend on genetic differences in CYP2C19. Individuals with certain CYP2C19 genotypes metabolize omeprazole differently, which can alter the degree of interaction with other drugs. For example, in people with the CYP2C19*1 allele, omeprazole is metabolized faster, and the effects of enzyme inducers or inhibitors (like rifampicin or fluvoxamine) on omeprazole metabolism are more pronounced . This genetic variability should be considered when predicting and managing DDIs.
Notable Drug Interactions
- Clopidogrel: Omeprazole can reduce the effectiveness of clopidogrel, an antiplatelet drug, increasing the risk of cardiovascular events in patients with heart conditions 110.
- Mycophenolate Mofetil: Omeprazole can decrease the absorption of mycophenolate mofetil, which is critical for transplant patients, potentially leading to organ rejection 110.
- Antivirals: Omeprazole can reduce the effectiveness of certain HIV medications like indinavir, nelfinavir, and atazanavir .
- Methotrexate, Tacrolimus, Digoxin, Itraconazole, Posaconazole, Oral Iron: Omeprazole can alter the pharmacokinetics of these drugs, sometimes leading to toxicity or reduced efficacy .
- Erythromycin: Omeprazole can decrease the metabolism of erythromycin via CYP3A4, but erythromycin does not significantly affect omeprazole metabolism .
- Levosulpiride: Co-administration with omeprazole does not result in significant pharmacokinetic changes for either drug .
- Mavacamten: Omeprazole increases mavacamten exposure by about 50%, but this is not considered clinically significant for most patients .
- Omecamtiv Mecarbil: No clinically significant interaction was observed when co-administered with omeprazole .
- Tunodafil: Tunodafil slightly increases omeprazole exposure in some genetic subgroups, but the effect is not significant in poor metabolizers .
Mechanisms Beyond Metabolism
Omeprazole can also affect drug absorption by increasing gastric pH, which can reduce the absorption of drugs that require an acidic environment, such as oral iron supplements and some antifungals .
Clinical Risk Management
The risk and severity of omeprazole-related DDIs depend on several factors, including the patient’s genotype, ethnicity, dose and duration of omeprazole therapy, the formulation of the co-administered drug, and the presence of other medications . In some cases, switching to another PPI or a histamine-2 antagonist may help avoid adverse interactions .
Monitoring and Recommendations
Patients on omeprazole, especially those with heart disease taking antiplatelet agents or transplant patients on mycophenolate, should be closely monitored for adverse effects and treatment failure . Therapeutic drug monitoring and careful review of medication regimens are recommended to minimize risks .
Conclusion
Omeprazole is associated with a range of drug interactions, mainly through effects on CYP2C19 and CYP3A4 enzymes and changes in gastric pH. The clinical significance of these interactions varies depending on the drugs involved, patient genetics, and other factors. Careful management, including consideration of alternative therapies and monitoring, is essential to ensure patient safety when omeprazole is used in combination with other medications 1247+1 MORE.
Sources and full results
Most relevant research papers on this topic
Inhibition of CYP2C19 and CYP3A4 by Omeprazole Metabolites and Their Contribution to Drug-Drug Interactions
Omeprazole metabolites contribute 30-63% to in vivo drug-drug interactions, but their relative abundance in circulation or logP values do not predict their contribution to in vivo DDI risk.
Drug interaction evaluation of the novel phosphodiesterase type 5 inhibitor tunodafil (youkenafil): effects of tunodafil on omeprazole pharmacokinetics based on CYP2C19 gene polymorphism, and effects of ritonavir on tunodafil pharmacokinetics.
Tunodafil slightly increases omeprazole exposure when combined with omeprazole, but ritonavir strongly inhibits tunodafil metabolism, and its combination with ritonavir should be prohibited.
DOI